moderate - Hospital admissions and elective procedures correlate with employment levels and insurance coverage rates, creating 0.5-0.7x GDP beta. However, critical care products (IV solutions, dialysis) are non-discretionary. Capital equipment purchases by hospitals are more cyclical, deferrable during recessions. International markets (40% revenue) show higher GDP sensitivity, particularly in emerging markets where out-of-pocket healthcare spending dominates.

Rising rates create dual pressure: (1) Hospital systems delay capital equipment purchases when borrowing costs increase, extending sales cycles 3-6 months; (2) Baxter's $6.8B debt load ($1.34 D/E ratio) increases interest expense, though 70% is fixed-rate. Higher rates compress MedTech valuation multiples as investors rotate from growth to value. Each 100bps rate increase adds ~$20M annual interest expense on floating debt.

value - Stock trades at 28.9x P/S (distorted by spin-off accounting) but normalized EV/EBITDA of 16x represents 20-25% discount to MedTech peers. Attracts deep value investors betting on post-separation margin recovery and turnaround specialists focused on manufacturing optimization. Dividend yield historically 2-3% appeals to income investors, though payout suspended during restructuring. Not a growth story given mature markets and generic competition.